undamentalytics Newsletter
Sign in

Co-diagnostics, Inc. cash flow statement

In fiscal 2025, Co-diagnostics, Inc.'s operations generated −$29.1m of cash; it spent $700,047 on capital projects, leaving free cash flow of −$29.8m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−3−4−628417−22−29−29−27
Depreciation and amortisation0000011111
Stock-based pay2113688521
Capital spending0001111110
Free cash flow−3−4−627405−23−30−30−27
Free cash flow after stock pay−5−5−72535−2−32−35−32−29
Share buybacks—————141———
Shares issued7051900————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CODX vs ITOCCODX vs PLSECODX vs IMDXCODX vs QTEX

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Co-diagnostics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Co-diagnostics, Inc.